Email this page: News Release
Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by Aradigm Corporation for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps Aradigm Corporation prevent automated submissions.